Pain can have different contributing mechanisms. Some pain presentations may include features commonly associated with neuropathic pain, such as burning, electric shocks, tingling, pins and needles, numbness, itching or altered sensation.
The DN4 was developed to help distinguish neuropathic pain features from non-neuropathic pain features using a short set of symptom and examination items.
It is commonly used in:
persistent pain assessment
nerve-related symptom screening
diabetic neuropathy research
post-surgical pain research
radicular pain contexts
chronic pain settings
referral-support documentation
The DN4 is useful because it combines symptom descriptors with simple sensory examination findings. However, it should still be interpreted as a screening tool, not a stand-alone diagnosis.
Outcome measure: Douleur Neuropathique 4 Questions
Abbreviation: DN4
Category: Neuropathic pain screening questionnaire
Type: Client-reported symptoms plus sensory examination
Number of items: 10
Score range: 0–10
Common cut-off: 4 or more out of 10
Higher score means: More neuropathic pain features reported or observed
Lower score means: Fewer neuropathic pain features
Best used for: Screening for neuropathic pain features
Key limitation: DN4 does not diagnose neuropathic pain or identify the cause on its own
The DN4 is a 10-item screening questionnaire.
It includes items related to:
burning
painful cold
electric shocks
tingling
pins and needles
numbness
itching
hypoesthesia to touch
hypoesthesia to pinprick
pain caused or increased by brushing
The first seven items are based on the client’s symptoms.
The final three items are based on simple sensory examination.
Each item is scored:
Yes = 1
No = 0
The total score ranges from 0 to 10.
A score of 4 or more is commonly used as a positive screening result.
The DN4 is used because neuropathic pain features may influence assessment reasoning, referral decisions and management planning.
A client may describe symptoms such as:
burning pain
electric-shock sensations
tingling
pins and needles
numbness
itching
altered sensitivity
pain from light touch
unusual cold pain
sensory changes
The DN4 may help professionals:
identify neuropathic pain features
support referral-aware screening
document symptom descriptors
guide further neurological or medical assessment where appropriate
compare symptoms over time
avoid relying only on pain intensity
improve communication about sensory symptoms
The DN4 should be interpreted alongside history, neurological findings, symptom distribution, medical history, physical assessment and professional judgement.
The DN4 measures features commonly associated with neuropathic pain.
It may provide insight into:
sensory descriptors
altered sensation
allodynia-like symptoms
hypoesthesia to touch
hypoesthesia to pinprick
neuropathic pain feature burden
whether further assessment may be needed
It does not directly measure:
diagnosis
nerve lesion
nerve disease
imaging findings
nerve conduction
tissue damage
pain mechanism with certainty
severity of injury
sport readiness
work readiness
The DN4 may be useful for:
rehabilitation practitioners
allied health support teams
exercise professionals working within scope
pain-informed movement professionals
movement assessment professionals
students learning screening tools
professionals documenting sensory symptom features
It may be relevant for clients with:
burning pain
electric-shock pain
numbness
tingling
pins and needles
altered skin sensitivity
pain after nerve injury
diabetic neuropathy features
radicular or radiating symptoms
post-surgical sensory symptoms
persistent pain with sensory descriptors
Use the DN4 when you want to screen whether pain has neuropathic features.
It may be useful at:
initial assessment
baseline pain screening
reassessment
persistent pain review
neurological symptom documentation
referral-support discussion
progress monitoring where neuropathic features are relevant
The DN4 is especially useful when the client describes sensory symptoms rather than only aching, soreness or mechanical pain.
Use caution when:
neurological symptoms are severe or worsening
red flags are present
symptoms are new, unexplained or rapidly progressing
the client cannot understand the descriptors
the professional is not trained to perform sensory testing
the result is being used as a diagnosis
the score is interpreted without broader assessment
The DN4 should not be used to:
diagnose neuropathic pain on its own
confirm a nerve lesion or disease
replace neurological assessment
replace medical assessment
explain symptoms on its own
determine treatment need
clear someone for sport
clear someone for work
replace professional judgement
You need:
DN4 questionnaire
scoring instructions
appropriate sensory testing materials
symptom notes
body chart or symptom map
baseline and retest dates
For sensory testing, the original DN4 includes touch and pinprick-related items. Professionals should only perform sensory testing that is appropriate to their training, setting and scope.
Explain the purpose of the questionnaire before starting.
Example wording:
“This questionnaire checks whether your pain has features commonly seen with neuropathic or nerve-related pain. It does not diagnose the cause, but it can help us decide whether further assessment may be useful.”
The DN4 includes:
symptom questions
sensory examination items
It can be completed as part of a structured pain assessment.
Ask the client to:
answer based on the pain being assessed
focus on the main painful area
describe whether each symptom is present or absent
ask for clarification if they do not understand a descriptor
report any unusual or uncomfortable responses during sensory testing
Each item is scored:
Yes = 1
No = 0
Total score range:
0–10
A score of 4 or more out of 10 is commonly used as a positive screening result.
Retest when useful, such as:
baseline
reassessment
after symptom change
after a flare-up
during persistent pain monitoring
before referral review
progress review
For consistency, record the same pain area, same version, symptom distribution, sensory testing method and current symptom context.
The DN4 includes sensory testing. Testing should be gentle and appropriate.
If the client reports worsening neurological symptoms, progressive weakness, bowel or bladder changes, saddle symptoms, severe unexplained pain or other red flags, further assessment or urgent referral may be required.
The DN4 score ranges from 0 to 10.
Higher scores indicate more neuropathic pain features.
Lower scores indicate fewer neuropathic pain features.
A commonly used cut-off is:
4 or more out of 10: positive screening result for neuropathic pain features
This cut-off should not be treated as a stand-alone diagnosis.
A higher DN4 score may suggest:
more neuropathic pain descriptors
sensory changes
possible neuropathic pain component
need for further neurological or medical assessment
value in documenting symptom distribution
referral consideration where appropriate
A high score does not prove neuropathic pain.
A lower DN4 score may suggest fewer neuropathic pain features.
A low score does not fully exclude neuropathic pain, especially if symptoms are intermittent, the wrong pain area is assessed, the client has difficulty describing symptoms or sensory testing is incomplete.
A DN4 score does not prove:
diagnosis
nerve lesion
nerve disease
pain mechanism with certainty
imaging findings
tissue damage
symptom cause
treatment need
sport readiness
work readiness
Example wording:
“Your DN4 result shows whether your pain has features commonly associated with neuropathic pain. It does not diagnose the cause, but it helps us decide whether further assessment or referral may be useful.”
For general fitness clients, DN4 may help identify whether sensory descriptors are relevant to their pain presentation.
Interpretation should include training history, symptom distribution and neurological screening where appropriate.
For athletes, neuropathic features may affect training tolerance, contact exposure, confidence and recovery.
DN4 should not be used to determine sport readiness on its own.
For older adults, interpretation should consider diabetes, medication context, comorbidities, balance, sensory loss, neurological history and general health.
For youth clients, consider comprehension, descriptor understanding and whether the measure is appropriate.
If assistance is provided, record it clearly.
For persistent pain, the DN4 may help identify neuropathic features within a broader pain presentation.
It should be combined with physical assessment, symptom history and referral-aware reasoning.
In clients with diabetes or known neurological conditions, DN4 may help document neuropathic features but should not replace medical assessment or neurological testing where indicated.
The DN4 is primarily a screening questionnaire, not a typical progress outcome measure.
High-quality, universally applicable MCID or MDC values are not usually used in the same way as disability questionnaires.
DN4 change should be interpreted with:
baseline comparison
symptom descriptor change
sensory findings
pain intensity
function change
medical context
neurological findings
professional judgement
A change from positive to negative screening status may be useful context, but it does not prove that a neuropathic mechanism has resolved.
The DN4 is not usually interpreted using general population norms.
It is commonly interpreted using the cut-off score of 4 or more out of 10.
Performance may vary by:
pain condition
language version
clinical setting
presence of sensory examination
pain distribution
disease context
assessor training
population being screened
Practical comparison guidance:
use the same version at retest
assess the same pain area
interpret the cut-off as screening only
combine the score with neurological and medical context
avoid using DN4 as a pass/fail diagnosis
The original DN4 validation study reported strong diagnostic accuracy for distinguishing neuropathic from non-neuropathic pain in the studied sample.
The questionnaire has since been translated and validated across multiple languages and clinical populations.
Evidence generally supports DN4 as a useful neuropathic pain screening tool, but performance varies across populations and settings.
Reliability and validity are strongest when:
the correct version is used
symptom descriptors are clearly explained
sensory examination items are performed appropriately
the pain area being assessed is clear
the result is interpreted with history and examination findings
the score is used as screening rather than diagnosis
Interpret cautiously when:
sensory testing is not performed
the client has difficulty understanding descriptors
symptoms are intermittent
pain is widespread or mixed-mechanism
neurological symptoms are rapidly changing
the score is used as a stand-alone diagnosis
Common errors include:
treating DN4 as a definitive diagnosis
using the cut-off without broader assessment
not clarifying the pain area being assessed
skipping sensory examination without noting it
ignoring red flags
ignoring neurological progression
assuming all tingling equals neuropathic pain
using DN4 to determine treatment or clearance alone
Limitations include:
screening tool only
score performance varies by population
sensory testing requires appropriate training
symptom descriptors may be misunderstood
neuropathic and non-neuropathic features can overlap
mixed pain mechanisms are common
it does not identify the cause of symptoms
it should not replace medical or neurological assessment where needed
The DN4 may help professionals:
document neuropathic pain features
support referral-aware reasoning
identify sensory descriptors
compare symptom features over time
guide further assessment decisions
communicate pain features more clearly
avoid relying only on pain intensity
For active clients, DN4 may help clarify whether symptoms such as burning, electric shocks, numbness or tingling should be considered during training modification or referral discussion.
For persistent pain clients, it can help document whether neuropathic features are part of a broader pain presentation.
The DN4 screens for symptoms and sensory findings commonly associated with neuropathic pain.
The DN4 has 10 items.
Each item is scored Yes = 1 and No = 0. The total score ranges from 0 to 10.
A score of 4 or more out of 10 is commonly used as a positive screening result.
No. DN4 is a screening tool and does not diagnose neuropathic pain on its own.
It asks about symptoms such as burning, painful cold, electric shocks, tingling, pins and needles, numbness and itching.
Yes. The full DN4 includes sensory examination items related to touch, pinprick and brushing.
No. It should be combined with history, symptom distribution, neurological findings, physical assessment and professional judgement.
DN4 is a 10-item neuropathic pain screening questionnaire.
It includes symptom descriptors and sensory examination items.
Scores range from 0 to 10.
A score of 4 or more is commonly used as a positive screening result.
DN4 does not diagnose neuropathic pain on its own.
It should be interpreted alongside history, neurological findings and broader assessment.
Red flags or worsening neurological symptoms require appropriate referral or escalation.
Bouhassira, D., Attal, N., Alchaar, H., Boureau, F., Brochet, B., Bruxelle, J., Cunin, G., Fermanian, J., Ginies, P., Grun-Overdyking, A., Jafari-Schluep, H., Lantéri-Minet, M., Laurent, B., Mick, G., Serrie, A., Valade, D., & Vicaut, E. (2005). Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain, 114(1–2), 29–36. https://doi.org/10.1016/j.pain.2004.12.010
Spallone, V., Morganti, R., D’Amato, C., Greco, C., Cacciotti, L., & Marfia, G. A. (2012). Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabetic Medicine, 29(5), 578–585. https://doi.org/10.1111/j.1464-5491.2011.03500.x
Timmerman, H., Steegers, M. A. H., Huygen, F. J. P. M., Goeman, J. J., van Dasselaar, N. T., Schenkels, M., Wilder-Smith, O. H. G., Wolff, A. P., & Vissers, K. C. P. (2017). Investigating the validity of the DN4 in a consecutive population of patients with chronic pain. PLOS ONE, 12(11), e0187961. https://doi.org/10.1371/journal.pone.0187961
Van Seventer, R., Vos, C., Giezeman, M., Meerding, W. J., Arnould, B., Regnault, A., van Eerd, M., Martin, C., & Huygen, F. J. P. M. (2013). Validation of the Dutch version of the DN4 diagnostic questionnaire for neuropathic pain. Pain Practice, 13(5), 390–398. https://doi.org/10.1111/j.1533-2500.2012.00558.x
